Elevra Lithium sells WA pegmatite rights to Wildcat for $16M plus royalty, reinvesting in North American lithium growth. Shares steady at $7.86.
Alpha Score of 48 reflects weak overall profile with strong momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Elevra Lithium (ASX:ELV) has sold its rights to the Tabba Tabba pegmatite project in Western Australia to Wildcat Resources (ASX:WC8) for $16 million plus an ongoing royalty, freeing up capital to focus on its North American assets.
The transaction covers licence E45/2364, with Wildcat assuming full ownership, control, and liability. Elevra will receive $5 million in cash on completion, $8 million in Wildcat shares priced at $0.353 each, and $3 million in deferred cash six months after Wildcat announces a feasibility study for Tabba Tabba. Elevra also gets A$0.70 per tonne for any JORC pegmatite resource Wildcat declares within the licence.
Managing Director Lucan Dow said the deal delivers immediate value from a non-core asset while keeping upside if Wildcat finds mineralisation. "This transaction delivers an attractive outcome for Elevra by unlocking immediate value from a non-core asset through a cash payment which can be reinvested in near-term growth initiatives," Dow said. "The structure also allows Elevra to benefit if any pegmatite mineralisation is discovered on E45/2364."
Elevra's North American portfolio includes a 100% stake in North American Lithium, a 60% holding in the Moblan project in Québec, and the wholly owned Carolina Lithium project in the US. The sale comes after Elevra set monthly production records and secured a financing package to support near-term growth.
Shares held steady at $7.86, giving the company a market cap of $1.52 billion.
For more on how this fits into broader stock market analysis, see the latest coverage.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.